Actinium Pharmaceuticals, Inc. financial data

Symbol
ATNM on NYSE
Industry
Pharmaceutical Preparations
Location
100 Park Ave., 23 Rd Floor, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
Cactus Ventures, Inc. (to 3/29/2013)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 970 % -9.82%
Debt-to-equity 111 % +32.6%
Return On Equity -57 % -75.8%
Return On Assets -47.9 % +3.49%
Operating Margin -3.31K % -51.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31.2M shares +13.8%
Common Stock, Shares, Outstanding 31.2M shares +13.8%
Entity Public Float 200M USD +67.5%
Common Stock, Value, Issued 31K USD +14.8%
Weighted Average Number of Shares Outstanding, Basic 31.1M shares +14.8%
Weighted Average Number of Shares Outstanding, Diluted 31.1M shares +14.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.03M USD -9.97%
Research and Development Expense 33.4M USD -12%
General and Administrative Expense 11.7M USD -22%
Operating Income (Loss) -45M USD +15%
Nonoperating Income (Expense) 4.04M USD +48.3%
Net Income (Loss) Attributable to Parent -40.9M USD +18.4%
Earnings Per Share, Basic -1.39 USD/shares +28%
Earnings Per Share, Diluted -1.39 USD/shares +28%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 78.7M USD -5.2%
Other Assets, Current 226K USD +248%
Assets, Current 79.5M USD -7.1%
Property, Plant and Equipment, Net 412K USD -31.4%
Operating Lease, Right-of-Use Asset 1.84M USD -24.5%
Assets 82.1M USD -7.68%
Liabilities, Current 7.76M USD -10.6%
Contract with Customer, Liability, Noncurrent 35M USD
Operating Lease, Liability, Noncurrent 1.14M USD -32.6%
Liabilities 43.9M USD -3.21%
Retained Earnings (Accumulated Deficit) -369M USD -12.5%
Stockholders' Equity Attributable to Parent 38.2M USD -12.3%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 57.2M USD -16.9%
Liabilities and Equity 82.1M USD -7.68%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.37M USD +51.1%
Net Cash Provided by (Used in) Financing Activities 14.8M USD +1818%
Net Cash Provided by (Used in) Investing Activities -11K USD +85.5%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 31.2M shares +13.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.4M USD -148%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 79M USD -5.17%
Deferred Tax Assets, Valuation Allowance 90.6M USD +19%
Operating Lease, Liability 1.95M USD
Payments to Acquire Property, Plant, and Equipment 11K USD -85.5%
Lessee, Operating Lease, Liability, to be Paid 2.12M USD
Operating Lease, Liability, Current 549K USD +5.37%
Lessee, Operating Lease, Liability, to be Paid, Year Two 630K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 466K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 165K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 643K USD
Deferred Tax Assets, Operating Loss Carryforwards 41.7M USD -5.73%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 380K USD
Operating Lease, Payments 153K USD +2%
Additional Paid in Capital 407M USD +9.56%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 89K USD -84.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%